Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.42 |
| ▸ | BRAF | P15056 | 10/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.40 |
| ▸ | STK10 | O94804 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056456 | 0.91 | ABL1 (0.50) | ABL1MAPK14BRAFKDRAXL | |
| SCHEMBL30681063 | 0.91 | ABL1 (0.75) | ABL1MAPK14BRAFFLT1KDR | |
| SCHEMBL2030799 | 0.91 | ABL1 (0.75) | ABL1MAPK14BRAFFLT1KDR | |
| SCHEMBL5054907 | 0.90 | ABL1 (0.61) | ABL1MAPK14BRAFFLT1KDR | |
| SCHEMBL5055222 | 0.89 | ABL1 (0.48) | ABL1MAPK14BRAFFLT1KDR | |
| SCHEMBL3076188 | 0.88 | ABL1 (0.71) | ABL1MAPK14BRAFFLT1KDR | |
| SCHEMBL30681081 | 0.88 | ABL1 (0.71) | ABL1MAPK14BRAFFLT1KDR | |
| SCHEMBL5052366 | 0.88 | ABL1 (0.47) | ABL1MAPK14BRAFFLT1KDR | |
| Hydrochloric Acid SCHEMBL2030220 | 0.88 | ABL1 (0.70) | ABL1MAPK14BRAFFLT1KDR | |
| SCHEMBL5055296 | 0.86 | ABL1 (0.65) | ABL1MAPK14BRAFFLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | ABL1 20/4885MAPK14 100/4885BRAF 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.